Jane E. Minturn, MD, PhD

Attending physician

Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine

Contact Jane E. Minturn, MD, PhD



This email address is being protected from spambots. You need JavaScript enabled to view it.


The Children's Hospital of Philadelphia Division of Oncology, 4028 CTRB 3501 Civic Center Boulevard


Pediatric Neuro-Oncology and Early Phase Clinic Trials/Developmental Therapeutics in Pediatric Brain Tumors. Particular interest in intratumoral hypoxia as a therapeutic target, a marker of treatment resistance, and a biomarker exploitable for non-invasive tumor imaging.

Signal transduction in embryonal tumors of the developing nervous system. Translating aberrantly expressed/activated neurodevelopmental signaling mechanisms into potential therapeutic targets

Signal transduction in embryonal tumors of the nervous system.


Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2006– present)


Ph.D., Neurobiology, Yale University (1996)
M.D., Medicine, Yale University School of Medicine (1996)
M.Phil., Neurobiology, Yale University (1993)
B.S., Psychobiology, Univeristy of Southern California (1986)

Extended Bio

I'm part of a small group that focuses specifically on brain tumors. Our multidisciplinary team includes oncologists, a neurologist, neurosurgeons, a radiation oncologist, social workers and a neuropsychologist, along with skilled nurse practitioners. This is the broad spectrum of expertise that The Children's Hospital of Philadelphia brings to treating its patients with brain tumors.

Treating cancer is a team effort at Children's Hospital, and we consider patients and their families a part of the team. Since our young patients are dependent on their parents for medical decision making, I try to give them a sense of some control over their disease, communicating in an age appropriate manner. Kids do much better, even when facing death, when they are part of the treatment plan and "secrets" are not kept from them.

I do both basic science and clinical research that focuses on developmental therapeutics in tumors of the nervous system. In particular I and my colleagues are looking at signal transduction in neuroblastoma and medulloblastoma. We are evaluating the biological effects of neurotrophin receptor expression on the growth properties of these tumors. Neurotrophins are able to signal certain cells to survive, mature or grow. The Trk family of neurotrophin receptors plays a critical role in these diverse behaviors.

We recently completed a clinical trial that targeted these receptors to inhibit signaling in neuroblastoma. The results are promising that this could be a therapeutic target for high risk neuroblastoma. We also are studying the way that Trk receptor molecules located on the surface of medulloblastoma cells regulate tumor growth and development. These studies may help to identify new therapeutic targets in the Trk signaling pathways.

As part of our approach to identifying new treatments for children with brain tumors, we are members of the multi-institutional Pediatric Brain Tumor Consortium (PBTC) and the Developmental Therapeutics Children's Oncology Group. These groups are involved in early phase clinical trials for relapsing and refractory brain tumors, with a particular focus on testing new, targeted treatments in children with brain tumors.

Our Children's Hospital team has partnered with drug development groups, and we are rapidly identifying drugs that show promise in patients with brain tumors who have no other curable option. There is a sense of urgency in our group -- we don't randomly test drugs but work collaboratively with laboratory scientists and drug development companies on rational, biologically-based targets. The best example of this is a drug for medulloblastoma that was recently rapidly brought to a PBTC clinical trial.

There is huge progress in getting promising drugs to kids with cancer. Through our cooperative group consortia, the pace is much more rapid than in past years, and Children's Hospital is a major part of the effort to help bring new agents to children with brain tumors.


Selected Publications

Iyer Radhika, Varela Carly R, Minturn Jane E, Ho Ruth, Simpson Anisha M, Light Jennifer E, Evans Audrey E, Zhao Huaqing, Thress Kenneth, Brown Jeffrey L, Brodeur Garrett M. AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts.. Cancer chemotherapy and pharmacology. Vol 70(3) . 2012 Sep:477-86.
Light Jennifer E, Koyama Hiroshi, Minturn Jane E, Ho Ruth, Simpson Anisha M, Iyer Radhika, Mangino Jennifer L, Kolla Venkatadri, London Wendy B, Brodeur Garrett M. Clinical significance of NTRK family gene expression in neuroblastomas.. Pediatric blood & cancer. Vol 59(2) . 2012 Aug:226-32.
Warren Katherine E, Gururangan Sri, Geyer J Russell, McLendon Roger E, Poussaint Tina Young, Wallace Dana, Balis Frank M, Berg Stacey L, Packer Roger J, Goldman Stewart, Minturn Jane E, Pollack Ian F, Boyett James M, Kun Larry E. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.. Journal of neuro-oncology. Vol 106(3) . 2012 Feb:643-9.
Norris Robin E, Minturn Jane E, Brodeur Garrett M, Maris John M, Adamson Peter C. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.. Cancer chemotherapy and pharmacology. Vol 68(6) . 2011 Dec:1469-75.
Minturn Jane E, Evans Audrey E, Villablanca Judith G, Yanik Gregory A, Park Julie R, Shusterman Suzanne, Groshen Susan, Hellriegel Edward T, Bensen-Kennedy Debra, Matthay Katherine K, Brodeur Garrett M, Maris John M. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.. Cancer chemotherapy and pharmacology. Vol 68(4) . 2011 Oct:1057-65.
Long Patrick M, Stradecki Holly M, Minturn Jane E, Wesley Umadevi V, Jaworski Diane M. Differential aminoacylase expression in neuroblastoma.. International journal of cancer. Journal international du cancer. Vol 129(6) . 2011 Sep:1322-30.
de Blank Peter M, Minturn Jane E. A rare case of ectopic recurrence of a craniopharyngioma diagnosed 17 years after initial presentation.. Journal of pediatric hematology/oncology. Vol 33(5) . 2011 Jul:392-7.
Ho Ruth, Minturn Jane E, Simpson Anisha M, Iyer Radhika, Light Jennifer E, Evans Audrey E, Brodeur Garrett M. The effect of P75 on Trk receptors in neuroblastomas.. Cancer letters. Vol 305(1) . 2011 Jun:76-85.
Haas-Kogan Daphne A, Banerjee Anuradha, Poussaint Tina Young, Kocak Mehmet, Prados Michael D, Geyer J Russell, Fouladi Maryam, Broniscer Alberto, Minturn Jane E, Pollack Ian F, Packer Roger J, Boyett James M, Kun Larry E. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas.. Neuro-oncology. Vol 13(3) . 2011 Mar:298-306.
Parsons D Williams, Li Meng, Zhang Xiaosong, Jones Siân, Leary Rebecca J, Lin Jimmy Cheng-Ho, Boca Simina M, Carter Hannah, Samayoa Josue, Bettegowda Chetan, Gallia Gary L, Jallo George I, Binder Zev A, Nikolsky Yuri, Hartigan James, Smith Doug R, Gerhard Daniela S, Fults Daniel W, VandenBerg Scott, Berger Mitchel S, Marie Suely Kazue Nagahashi, Shinjo Sueli Mieko Oba, Clara Carlos, Phillips Peter C, Minturn Jane E, Biegel Jaclyn A, Judkins Alexander R, Resnick Adam C, Storm Phillip B, Curran Tom, He Yiping, Rasheed B Ahmed, Friedman Henry S, Keir Stephen T, McLendon Roger, Northcott Paul A, Taylor Michael D, Burger Peter C, Riggins Gregory J, Karchin Rachel, Parmigiani Giovanni, Bigner Darell D, Yan Hai, Papadopoulos Nick, Vogelstein Bert, Kinzler Kenneth W, Velculescu Victor E. The genetic landscape of the childhood cancer medulloblastoma.. Science (New York, N.Y.). Vol 331(6016) . 2011 Jan:435-9.